Abstract:Ya-Hui Chen, 1, 2 Yi-Chun Chen, 1 Chi-Chen Lin, 3– 5 Yao-Peng Hsieh, 6– 8 Chien-Sheng Hsu, 9 Ming-Chia Hsieh 1, 10 1 Diabetes Research Laboratory, Department of Research, Changhua Christian Hospital, Changhua, Taiwan; 2 Institute of Biochemistry and Biotechnology, Chung Shan Medical University, Taichung, Taiwan; 3 Institute of Biomedical Science, National Chung-Hsing University, Taichung, Taiwan; 4 Department of Health and Nutrition, Asia University, Taichung, Taiwan; 5 Department of Medical Research, China Medical University Hospital, Taichung, Taiwan; 6 Division of General Internal Medicine, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan; 7 School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; 8 School of Medicine, Chung Shan Medical University, Taichung, Taiwan; 9 Frontier Molecular Medical Research Center in Children, Changhua Christian Children Hospital, Changhua, Taiwan; 10 Intelligent Diabetes Metabolism and Exercise Center, China Medical University Hospital, Taichung, Taiwan Correspondence: Ming-Chia Hsieh Email D94750@mail.cmuh.org.tw Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with an overall 5-year survival rate of 9.3%, and this malignancy is expected to become the second leading cause of cancer-related death by 2030. Gemcitabine resistance develops within weeks of PDAC patient's chemotherapeutic initiation. Statins, including pitavastatin, have been indicated to have anticancer effects in numerous human cancer cell lines. Thus, in this study, we hypothesized that a combination of gemcitabine and pitavastatin may have a greater anticancer effect than gemcitabine alone on the human pancreatic carcinoma cell line MIA PaCa-2. Methods: The anticancer effects of gemcitabine with pitavastatin were evaluated using human MIA PaCa-2 cell line in vitro and in vivo Balb/c murine xenograft tumor model. Cell viability was assessed with CCK-8, and cell migration was stained by crystal violet. Cell cycle distribution, apoptosis and mitochondrial membrane potential were examined by flow cytometry. Activation of drug transporters (hENTs, hCNTs), intracellular drug activating (dCK) and inhibition of inactivating enzymes (RRMs) pathways were assessed by Western blotting analysis. Molecular mechanisms and signaling pathways of apoptosis, necrosis and autophagy also were assessed by Western blotting. Results: We observed that gemcitabine and pitavastatin synergistically suppressed the proliferation of MIA PaCa-2 cells through causing sub-G1 and S phase cell cycle arrest. Activation of apoptosis/necrosis was confirmed by annexin V/propidium iodide double staining, which showed increasing levels of active caspase 3, cleaved poly(ADP-ribose) polymerase and the RIP1–RIP3–MLKL complex. Moreover, gemcitabine–pitavastatin-mediated S phase arrest downregulated cyclin A2/CDK2 and upregulated p21/p27 in MIA PaCa-2 cells. Furthermore, this combination improved drug cellular metabolism pathway, mitochondria function and activated autophagy as part of the cell death mechanism. In vivo, gemcitabine-pitavastatin effectively inhibited tumor growth in a nude mouse mode of Mia PaCa-2 xenografts without observed adverse effect. Conclusion: Combined gemcitabine–pitavastatin may be an effective novel treatment option for pancreatic cancer. Keywords: synergistic anticancer, gemcitabine, pitavastatin, pancreatic cancer, MIA PaCa-2

Extensive DNA Damage and Loss of Cell Viability Occur Synergistically With the Combination of Recombinant Methioninase and Paclitaxel on Pancreatic Cancer Cells which Report DNA-Damage Response in Real Time

Synergistic Antitumor Efficacy of Rmv-Hu191 and Olaparib in Pancreatic Cancer by Generating Oxidative DNA Damage and ROS-dependent Apoptosis

Depletion of Paraspeckle Protein 1 Enhances Methyl Methanesulfonate-Induced Apoptosis Through Mitotic Catastrophe

Perspectives on the Combination of Radiotherapy and Targeted Therapy with DNA Repair Inhibitors in the Treatment of Pancreatic Cancer.

Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells

Paclitaxel And Ceramide Synergistically Induce Cell Death With Transient Activation Of Egfr And Erk Pathway In Pancreatic Cancer Cells

Synergistic Anticancer Effects of Gemcitabine with Pitavastatin on Pancreatic Cancer Cell Line MIA PaCa-2 in vitro and in vivo

Met Inhibitor Enhances Efficacies Of Gemcitabine And Olaparib In Pancreatic Cancer Cells.

Methionine Restriction Increases Exosome Production and Secretion in Breast Cancer Cells

MicroRNA-128-3p Regulates Mitomycin C-induced DNA Damage Response in Lung Cancer Cells Through Repressing SPTAN1.

Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression

Combinatorial Approaches to Enhance DNA Damage following Enzyme-Mediated Depletion of L-Cys for Treatment of Pancreatic Cancer

Methionine Restriction Reduces Lung Cancer Progression and Increases Chemotherapy Response

First-line Chemotherapy in Combination With Oral Recombinant Methioninase and a Low-methionine Diet for a Stage IV Inoperable Pancreatic-Cancer Patient Resulted in 40% Tumor Reduction and an 86% CA19-9 Biomarker Decrease

MicroRNA-148b and microRNA-152 reactivate tumor suppressor genes through suppression of DNA methyltransferase-1 gene in pancreatic cancer cell lines

A CANCER PERSISTENT DNA REPAIR CIRCUIT DRIVEN BY MDM2, MDM4 (MDMX), AND MUTANT P53 FOR RECRUITMENT OF MDC1 AND 53BP1 TO CHROMATIN

Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy

Applying Proteomic Methodologies to Analyze the Effect of Methionine Restriction on Proliferation of Human Gastric Cancer SGC7901 Cells.

Differential induction of apoptosis and senescence by the DNA methyltransferase inhibitors 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumor cells

Abstract LB_C03: Protein translation inhibition enforces histone deacetylase inhibitor activity resulting in synergistic pancreatic cancer cell death

Combination Therapy with Epigenetic-Targeted and Chemotherapeutic Drugs Delivered by Nanoparticles to Enhance the Chemotherapy Response and Overcome Resistance by Breast Cancer Stem Cells.